Application of mass spectrum technology to detection of molecular level of PSM-E in urine in preparation of product for early diagnosis of prostate cancer

Abstract

The invention discloses application of A mass spectrum technology to detection of molecular level of PSM-E in urine in preparation of product for early diagnosis of prostate cancer A urine protein sample is diluted and then is directly introduced into a liquid chromatography-electrospray ionization-tandem mass spectrometer for determination, and the content level of the PSM-E in the urine can be rapidly and accurately detected; a fully-synthesized PSM-E characteristic peptide standard substance is adopted as an internal standard quantitative analysis substance, so that errors caused in a sample pretreatment process are reduced; the selectivity and the accuracy of the method are better improved by the liquid chromatography-tandem mass spectrometry; through selection and optimization of a chromatographic column and elution conditions, the chromatographic separation process is improved, and the chromatographic analysis time is shortened. According to the invention, the quantitative detection of the PSM-E in the urine sample can be realized, the operation is simple, the application is convenient, the content of the PSM-E in the urine can be used as a specific biomarker for detecting the prostatic cancer, and an efficient and feasible technical method is provided for early screening of the prostatic cancer.

Description

Technical field

[0001] The present invention relates to the field of clinical testing, in particular, to mass spectrometry techniques to detect PSM-E molecular levels in urine in the preparation of early diagnostic prostate cancer products. Background technique

[0002] According to the "2020 National Cancer Center Annual Work Report", the incidence of prostate cancer in my country is ranked ninth (total population), and the mortality is ranked eighth (total population). my country's prostate cancer has increased rapid incidence, and the age of onset is gradually emerging. Moreover, 60% to 70% of patients with prostate cancer are already local late or late. At present, there is a lack of accurate and convenient prostate cancer screening techniques at home and abroad. Prostate Specific Membranentigen (PSMA) is a cross-membrane glycoprotein having a hydrolyzed folic acid and neurotransmitter N-acetyl asparamide function, high expression in prostate cancer, which uses it as a diagno...

Images